Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;39(8):1636-1647.
doi: 10.1111/jgh.16554. Epub 2024 May 2.

Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians

Tingfeng Wu  1   2 , Junzhao Ye  1 , Suilin Mo  3 , Miaosheng Ye  4 , Xiaoyi Li  5 , Qing Li  6 , Wengeng Wang  7 , Qiaocong Zheng  8 , Ke Luo  9 , Yi Zhang  10 , Shouwei Tu  11 , Daituan Che  12 , Rulong Gong  13 , Xing Chen  14 , Rong Miu  15 , Congxiang Shao  1 , Yanhong Sun  16 , Bihui Zhong  1
Affiliations

Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians

Tingfeng Wu et al. J Gastroenterol Hepatol. 2024 Aug.

Abstract

Background and aim: The introduction of the latest nomenclature, metabolic associated steatotic liver disease (MASLD), proposed by the multi-society without Asian society consensus statement, aims to redefine the diagnostic criteria for metabolic associated fatty liver disease (MAFLD). However, its effect on the epidemiology in Asia remains unclear.

Method: We conducted a population-based cross-sectional survey on fatty liver disease using multistage stratified random sampling of participants from Guangzhou, a representative area in China (ChiCTR2000033376). Demographic, socioeconomic, lifestyle, and laboratory data were collected. Hepatic steatosis and the severity of fibrosis were assessed using FibroScan.

Results: A total of 7388 individuals were recruited, the proportion of which meeting the definitions for nonalcoholic fatty liver disease (NAFLD), MAFLD, and MASLD were 2359 (31.9%), 2666 (36.1%), and 2240 (30.3%), respectively. One hundred and twenty (1.6%) patients had cryptogenic SLD, and 537 (7.3%) patients were diagnosed with MetALD. MASLD did not significantly differ from NAFLD and MAFLD, except that MAFLD patients had a lower proportion of males, hypertension, and diabetes and were less likely to consume tea (P < 0.05). Both cryptogenic SLD and MASLD non-MAFLD patients exhibited milder hepatic steatosis and a lower frequency of liver injury than NAFLD, MAFLD, or MASLD patients (all P < 0.05). An increased HOMA-IR (adjusted OR: 1.33, 95% CI: 1.10-2.03) was associated with higher risk of moderate-to-severe steatosis for MASLD non-MAFLD patients, while consuming more cups of tea (P for trend = 0.015) showed inverse associations.

Conclusion: Irrespective of terminology used is that fatty liver disease is highly prevalent in the Han Chinese population. Differences in insulin resistance and lifestyle risk factors are associated with redefinition disparities.

Keywords: metabolic associated fatty liver disease; nonalcoholic fatty liver disease; prevalence; steatotic liver disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Eslam M, Sanyal AJ, George J et al. MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999–2014.e1.
    1. Rinella ME, Lazarus JV, Ratziu V et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol. 2023; 20: 101133.
    1. Man S, Deng Y, Ma Y et al. Prevalence of liver steatosis and fibrosis in the general population and various high‐risk populations: a nationwide study With 5.7 million Adults in China. Gastroenterology 2023; 165: 1025–1040.
    1. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 2023; 79: 842–852.
    1. Vaz K, Clayton‐Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, Roberts SK. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023.

LinkOut - more resources